Doxorubicin in Veterinary Oncology: Infusion and Cumulative-Risk Profile

Doxorubicin is an anthracycline cytotoxic chemotherapy drug used by veterinary oncologists for lymphoma and several sarcomas and carcinomas. Companion-animal use is veterinarian-directed and generally extra-label, with drug-specific infusion and cumulative-risk safeguards.

Doxorubicin interferes with cancer-cell DNA through several mechanisms and must be administered intravenously by trained personnel. It is a vesicant: leakage outside the vein can cause severe tissue injury. This directory page does not provide a dose, interval or lifetime limit.

It may be used within a multi-agent lymphoma protocol or as part of treatment for selected hemangiosarcoma, osteosarcoma, soft-tissue sarcoma and carcinoma cases. Selection depends on diagnosis, stage, previous therapy, heart and organ health, and the intended balance of benefit and burden.

The treatment goal may be remission, delay of recurrence, control of measurable disease or symptom benefit. The team should explain how response is measured and how cumulative exposure changes later choices.

Clinic protocols commonly include examination and blood-count checks before treatment, secure intravenous access and observation during infusion. Cardiac assessment may be recommended based on the dog, breed, examination, history and cumulative exposure; cats require kidney-focused consideration.

Merck Veterinary Manual describes veterinary indications and major toxicities, including myelosuppression, severe extravasation injury, cumulative cardiomyopathy in dogs and cumulative kidney toxicity in cats. AAHA guidance supports individualized chemotherapy monitoring and client communication.

Possible effects include appetite loss, vomiting, diarrhea or colitis, reduced blood-cell counts and infusion reactions. Urgent contact is warranted for fever, marked lethargy, repeated gastrointestinal signs, blood in stool, breathing change, collapse or any concern that drug escaped the vein during treatment.

The oncology team must coordinate other chemotherapy, cardiotoxic or marrow-suppressive drugs, radiation, anesthesia and supplements. Doxorubicin is hazardous; caregivers should follow written precautions for body waste and contaminated materials rather than improvising.